| abstract |
A pharmaceutical combination, comprising (i) a MET tyrosine kinase inhibitor which is INC280 having the formula ** (See formula) ** or a pharmaceutically acceptable salt thereof, (ii) an EGFR tyrosine kinase inhibitor which is (R, E) -N- (7-chloro-1- (1- (4- (dimethylamino) but-2-enoyl) azepan-3-yl) -1Hbenzo [d] imidazol-2-yl) -2 -methylisonicotinamide, or a pharmaceutically acceptable salt or hydrate thereof. |